The point of an extended suspension, page-8

A large chunk of this company has already been sold; 20 % of to SB at a average sp of between 10-13.5 cents, and counting (ref: increased stake holding in the future, (?) )

This should not be a issue, self preservation, unless there are serious underlying issues; if those issues have credence then this company may as well stay in suspension.

Retailers do not call the shots in the long run, funds and sophisticated investors do, imo, they lead (latter) and the retailers can follow fairly safely.

MORE than one large shareholder required, one major sh can call the shots to their advantage, their advantage will not be, arguably, to the advantage of retail sh’s, simple maths.

Why not rival suitors evident?  To come on board in the future?, absolutely required to do so, imho, rival interests will/should push up the value, this should flow on to retail investors.

One suitor, aka; SB ..... game plan??, take ‘private’ then sell of; Medical division, IP of the Adapt platform and wholly concentrate funds to R&D the Immunology Division? 


Personally, hope they are here to add/create value and move on.


From time immemorial, there has been the assumption that Admedus IP is cutting edge/superior, I have said this at times and at times said ‘IF’.


What belies this claim is the fact that it still has not been successfully commercialised, WP says it is, (superior)  KOL (?)  say it is, adverse studies/reports have countered this.




Remark made that Admedus IP failure (?) still a better result than rival products; question is HOW much better; marginally or significant! To what extent BEFORE it is recognised as to the go to product, IF only marginally superior WHY would you chance against a ‘proven’ product from Edwards Life Sciences and like.


If signficantly superior? What’s the bottleneck?, enough time has elapsed to prove its worth, what of the ‘halo’ effect; ref CardioCel?


Sales team?, Conservatism of the Medical profession? OR the IP under doubt?, that is; not superior ENOUGH to gain traction against market giants.


WP here to ‘talk’ the company up, KOLs (?) ‘support’ the ‘talk’, adverse reports negate that, who does the ‘retailer’ take notice of? ..... sp supports the adverse reports, imo, what ‘factor’ will change sentiment to ‘postive’?